Sorafenib is effective for imatinib-resistant FIP1L1/PDGFRA T674I mutation-positive acute myeloid leukemia with eosinophilia

Leuk Lymphoma. 2013 Aug;54(8):1788-90. doi: 10.3109/10428194.2012.749469. Epub 2012 Dec 26.
No abstract available

Publication types

  • Letter

MeSH terms

  • Antineoplastic Agents / therapeutic use*
  • Benzamides / pharmacology
  • Benzamides / therapeutic use
  • Drug Resistance, Neoplasm / genetics
  • Humans
  • Imatinib Mesylate
  • Leukemia, Myeloid, Acute / complications
  • Leukemia, Myeloid, Acute / drug therapy*
  • Leukemia, Myeloid, Acute / genetics*
  • Mutation*
  • Niacinamide / analogs & derivatives*
  • Niacinamide / therapeutic use
  • Phenylurea Compounds / therapeutic use*
  • Piperazines / pharmacology
  • Piperazines / therapeutic use
  • Pyrimidines / pharmacology
  • Pyrimidines / therapeutic use
  • Receptor, Platelet-Derived Growth Factor alpha / genetics*
  • Sorafenib
  • Treatment Outcome
  • mRNA Cleavage and Polyadenylation Factors / genetics*

Substances

  • Antineoplastic Agents
  • Benzamides
  • FIP1L1 protein, human
  • Phenylurea Compounds
  • Piperazines
  • Pyrimidines
  • mRNA Cleavage and Polyadenylation Factors
  • Niacinamide
  • Imatinib Mesylate
  • Sorafenib
  • Receptor, Platelet-Derived Growth Factor alpha